Literature DB >> 27858165

NMR study of the effects of some bleomycin C-termini on the structure of a DNA hairpin with the 5'-GC-3' binding site.

Teresa E Lehmann1, Sally A Murray2, Azure D Ingersoll2, Teresa M Reilly2, Shelby E Follett2, Kevin E Macartney2, Mark H Harpster2.   

Abstract

The antibiotics known as bleomycins constitute a family of natural products clinically employed for the treatment of a wide spectrum of cancers. The drug acts as an antitumor agent by virtue of the ability of a metal complex of the antibiotic to cleave DNA. Bleomycins are differentiated by their C-terminal regions. Previous structural studies involving metal-bleomycin-DNA triads have allowed the identification of the bithiazole-(C-terminus substituent) segment in this molecule as the one that most closely interacts with DNA. Three different modes of binding of metallo-bleomycins to DNA (partial or total intercalation of the bithiazole unit between DNA bases, or binding to the minor groove) have been proposed in the literature. The therapeutic use of bleomycin is frequently associated with the development of pulmonary fibrosis. The severity of this side effect has been attributed to the C-terminus of the antibiotic by some researchers. The degree of pulmonary toxicity of bleomycin-A2 and -A5, were found to be higher than those of bleomycin-B2 and peplomycin. Since the introduction of Blenoxane to clinical medicine in 1972, attempts have been made at modifying the basic bleomycin structure at the C-terminus to improve its therapeutic index. However, the pharmacological and toxicological importance of particular C-termini on bleomycin remains unclear. The present study was designed to determine the effect of Zn(II)bleomycin-A2, -A5, -B2, and Zn(II)peplomycin on the structure of a DNA hairpin containing the 5'-GC-3' binding site. We provide evidence that different Zn(II)bleomycins affect the structure of the tested DNA segment in different fashions.

Entities:  

Keywords:  Anticancer drug; DNA; NMR; Pulmonary fibrosis; Structure–function

Mesh:

Substances:

Year:  2016        PMID: 27858165      PMCID: PMC5950717          DOI: 10.1007/s00775-016-1413-4

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  31 in total

1.  Possible structural role of the disaccharide unit in Fe-bleomycin before and after oxygen activation.

Authors:  Teresa E Lehmann; Yang Li
Journal:  J Antibiot (Tokyo)       Date:  2011-11-09       Impact factor: 2.649

2.  Coordination chemistry of co(II)-bleomycin: its investigation through NMR and molecular dynamics.

Authors:  T E Lehmann; M L Serrano; L Que
Journal:  Biochemistry       Date:  2000-04-11       Impact factor: 3.162

3.  Pulmonary toxicity of bleomycin analogs.

Authors:  I H Raisfeld
Journal:  Toxicol Appl Pharmacol       Date:  1980-12       Impact factor: 4.219

Review 4.  A review of clinical studies of pepleomycin.

Authors:  S Oka
Journal:  Recent Results Cancer Res       Date:  1980

5.  Solution structure of the hydroperoxide of Co(III) phleomycin complexed with d(CCAGGCCTGG)2: evidence for binding by partial intercalation.

Authors:  Wei Wu; Dana E Vanderwall; Christopher J Turner; Silvia Hoehn; Jingyang Chen; John W Kozarich; JoAnne Stubbe
Journal:  Nucleic Acids Res       Date:  2002-11-15       Impact factor: 16.971

6.  Molecular modeling of the three-dimensional structure of Fe(II)-bleomycin: are the Co(II) and Fe(II) adducts isostructural?

Authors:  Teresa E Lehmann
Journal:  J Biol Inorg Chem       Date:  2001-10-12       Impact factor: 3.358

7.  Structures of HO(2)-Co(III)bleomycin A(2) bound to d(GAGCTC)(2) and d(GGAAGCTTCC)(2): structure-reactivity relationships of Co and Fe bleomycins.

Authors:  Chunqing Zhao; Chuanwu Xia; Qunkai Mao; Holger Försterling; Eugene DeRose; William E Antholine; Witold K Subczynski; David H Petering
Journal:  J Inorg Biochem       Date:  2002-07-25       Impact factor: 4.155

8.  Combination cisplatin, vinblastine, and bleomycin chemotherapy (PVB) for malignant germ-cell tumors of the ovary.

Authors:  R W Carlson; B I Sikic; M M Turbow; S C Ballon
Journal:  J Clin Oncol       Date:  1983-10       Impact factor: 44.544

9.  [Toxicological studies on pepleomycin sulfate (NK631). VI. Chronic toxicity of pepleomycin in dogs (author's transl)].

Authors:  K Ito; J Handa; Y Irie; H Ezura; M Kumagai; Y Irie; A Suzuki; T Hagiwara; H Yamane; K Miyamoto; T Yamashita; M Tsubosaki; A Matsuda; N Konoha
Journal:  Jpn J Antibiot       Date:  1979-03

10.  Biological studies on the degradation products of 3-[(S)-1'-phenylethylamino]propylaminobleomycin: a novel analog (pepleomycin).

Authors:  K Takahashi; H Ekimoto; S Aoyagi; A Koyu; H Kuramochi; O Yoshioka; A Matsuda; A Fujii; H Umezawa
Journal:  J Antibiot (Tokyo)       Date:  1979-01       Impact factor: 2.649

View more
  2 in total

1.  Structural changes of Zn(II)bleomycin complexes when bound to DNA hairpins containing the 5'-GT-3' and 5'-GC-3' binding sites studied through NMR spectroscopy.

Authors:  Shelby E Follett; Sally A Murray; Azure D Ingersoll; Teresa M Reilly; Teresa E Lehmann
Journal:  Magnetochemistry       Date:  2017-12-27

2.  Interaction of Zn(II)bleomycin-A2 and Zn(II)peplomycin with a DNA hairpin containing the 5'-GT-3' binding site in comparison with the 5'-GC-3' binding site studied by NMR spectroscopy.

Authors:  Shelby E Follett; Azure D Ingersoll; Sally A Murray; Teresa M Reilly; Teresa E Lehmann
Journal:  J Biol Inorg Chem       Date:  2017-07-26       Impact factor: 3.358

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.